Drug Profile
PL 265
Alternative Names: IC-805; PL-265Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Pharmaleads
- Class Amides; Analgesics; Biphenyl compounds; Non-opioid analgesics; Phosphorus compounds; Small molecules
- Mechanism of Action Aminopeptidase inhibitors; Neprilysin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer pain; Dry eyes; Inflammatory pain; Neuropathic pain; Ocular pain
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Inflammatory-pain in France (PO)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Ocular-pain in France (PO)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Cancer-pain in France (Intrathecal)